Research presented at TVT 2019 in Chicago last week suggests a transcarotid approach to transcatheter aortic valve replacement is favorable for patients unable to tolerate femoral access, topping both transapical and transaortic approaches as the preferable route for alternate-access TAVR.  

Physicians are facing a new issue as TAVR expands to younger populations—an increased incidence of bicuspid aortic stenosis.

The undertreatment of aortic stenosis in the U.S. is severe, driven by deep-rooted racial and sex disparities and a disconnect between patients and their clinicians.

After years of limited success, researchers have found a way to convert type A blood cells into the more universal type O by leveraging human gut bacteria, according to a report in the magazine Science.

Canadian researchers have singled out a peptide known as apelin that could improve survival in CV patients with aortic aneurysms, leading them to dub the molecule the equivalent of insulin for heart disease.

Teva Pharmaceuticals is pulling six bulk lots of its angiotensin II receptor blocker losartan from the market after testing revealed dangerously high levels of N-Nitroso-N-methyl-4-aminobutyric acid, a probable human carcinogen, in the drugs.

A collaboration between cardiologists and dentists at the Karolinska Institutet in Sweden has linked undetected glucose disorders like diabetes to an increased risk of myocardial infarction and periodontitis, a severe gum disease.

Heart patients with untreated white coat hypertension are more than twice as likely to die from cardiovascular disease as their normotensive counterparts, according to a June 11 study.